

## **AACR 2026 Preview | Elpiscience's FIC CD39/TGF- $\beta$ BsAb ES014**

### **Selected for Poster Presentation**

Elpiscience announced that its independently developed, first-in-class CD39/TGF- $\beta$  bispecific antibody (bsAb), ES014, has been selected for poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The latest research findings will be presented on-site on April 20.

AACR is one of the oldest and largest professional organizations dedicated to cancer research worldwide. The AACR Annual Meeting is a premier international event in oncology, bringing together tens of thousands of leading scientists, clinicians, and industry leaders to share cutting-edge research and advances in cancer science and drug development, and is widely regarded as a key barometer for global cancer research and innovation. The 117th AACR Annual Meeting will take place from April 17 to 22, 2026, in San Diego, United States.

ES014 is a first-in-class and the first clinical-stage CD39/TGF- $\beta$  bsAb worldwide. It is designed to simultaneously target two key immunosuppressive pathways in the tumor microenvironment — the CD39-adenosine pathway and the TGF- $\beta$  pathway. In February 2026, ES014 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

Results from a Phase I clinical study demonstrated that ES014 exhibited encouraging anti-tumor activity as a monotherapy and a favorable safety profile across multiple solid tumors, including non-small cell lung cancer, gastrointestinal stromal tumors, and desmoid tumors, highlighting its broad therapeutic potential.

The selection of this study for poster presentation at the AACR Annual Meeting underscores growing international academic interest in ES014's novel mechanism of action and clinical potential, and provides further support for its ongoing clinical development.

#### **Poster Presentation Details:**

- Abstract Title: First-in-human study of ES014 (CD39/TGF- $\beta$  bispecific antibody) as monotherapy in advanced solid tumors
- Session Topic Tract: Clinical Research
- Session Title: Phase 0 and First-in-Human Phase I Clinical Trials
- Time: April 20, 2026, 2:00 PM – 5:00 PM (PT)
- Location: Poster Section 51, Board 19



- Abstract Number: CT127

Further details will be disclosed during the conference.

### **About Elpiscience**

Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. By advancing breakthrough biologics and leveraging global strategic partnerships, Elpiscience has built a differentiated pipeline to deliver transformative treatment solutions for patients worldwide.

**For more information about Elpiscience, please visit <https://www.elpiscience.com/>.**

#### **BD inquiries:**

[BD@elpiscience.com](mailto:BD@elpiscience.com)

#### **Media inquiries:**

[PR@elpiscience.com](mailto:PR@elpiscience.com)